Draupnir Bio raises €30.0M Series A round
31 October 2019· Copenhagen, Denmark· health, drug_discovery, biotech, b2b, deep_hardware
The funding was used to develop small molecule therapeutics targeting the PCSK9 protein to transform the treatment of heart disease.
Investors
LeadNovo Seeds
Also participating
High-Tech GründerfondsGilde HealthcareINKEF Capital
About Draupnir Bio
Stage
Seed
Headquarters
Copenhagen, Denmark
Founded
2017
Team Size
6–20
Sectors
healthdrug_discoverybiotechb2bdeep_hardware
Source: https://draupnir.bio/news/draupnir-bio-secures-euro-30-million-in-series-a-funding-round/